Histogenics Corporation

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Gilead Teams With Insitro On

The first couple of weeks of January usually are pretty remarkable in terms of new venture capital financings announced by biopharmaceutical firms and VC deals revealed in 2019 are living up to past y

Histogenics Corp. believes that the US FDA will accept data from a Phase III study of its knee cartilage cell therapy NeoCart for review, even though the study failed the primary endpoint, because

IN VITRO DIAGNOSTICS Financings HTG Molecular Diagnostics Inc. HTG Molecular Diagnostics Inc. netted $37.9mm through a public offering of 13.9mm common shares (including the overallotment) at $2.9